Supporting the healthy future of people around the world with biotechnology
Products
Veterinary Vaccines
Meiji Animal Health Co., Ltd.
KM Biologics has transferred its animal health business to its subsidiary, Meiji Animal Health Co., Ltd.
KM Biologics has transferred its animal health business to its subsidiary, Meiji Animal Health Co., Ltd.
Contact us to unfold a world of possibilities
NEWS
- Mar. 4, 2025
- Meiji Seika Pharma Invests in Osivax SAS
- Jan. 27, 2025
- Japanese Government Delivers KM Biologics' Mpox Vaccine to the Democratic Republic of the Congo
- Nov. 20, 2024
- KM Biologics Receives WHO Emergency Use Listing for its Mpox Vaccine
- Sep. 10, 2024
- Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan
- Jul. 10, 2024
- KM Biologics is Selected Through an Open Call for Conducting the ”Large-scale Vaccine Clinical Study Project“ by the Ministry of Health, Labour and Welfare
Meiji Holdings
KM Biologics is a member of the Meiji Group. Learn more about Meiji Holdings.
